The production of nucleic acid-based therapeutics and diagnostics is often hampered by inefficient synthesis methods that yield lower purity oligonucleotides and require extensive purification, increasing costs and development timelines. Traditional monomer-based synthesis can result in impurities, such as shorter chain lengths, which can affect the efficacy and safety of the final product.

NATiAS Inc. offers a suite of nucleic acid products and contract manufacturing services leveraging its proprietary Blockmer® technology to streamline oligonucleotide synthesis and produce high-purity nucleic acid APIs. Blockmer® technology significantly shortens the synthesis process compared to conventional methods, enabling faster production and reduced costs. By using pre-synthesized blocks of nucleotides, NATiAS minimizes the formation of truncated sequences and other impurities, resulting in highly defined and consistent oligonucleotide products. The company provides custom oligonucleotide synthesis services, as well as a catalog of Blockmer® reagents and CpG ODN adjuvants. NATiAS's GMP manufacturing capabilities support the development of nucleic acid-based therapeutics from early-stage research to commercialization.

Blockmer® technology for accelerated oligonucleotide synthesis

High-purity nucleic acid APIs with minimal truncated sequences

Customizable Blockmer® reagents with diverse structural options

Contract manufacturing services for nucleic acid-based therapeutics and diagnostics

CpG ODN adjuvants for vaccine development and immunotherapy

GMP-compliant manufacturing and quality control

Capabilities for both solid-phase and liquid-phase synthesis

NATiAS serves pharmaceutical and biotechnology companies involved in developing nucleic acid-based therapeutics, diagnostics, and vaccines, as well as research institutions requiring high-quality oligonucleotides.